Our model also provides a rational explanation for why in multiple cancer types, malignant tumours tend to reduce EPHB6 expression [37], since a decrease in EPHB6 levels should improve survival of cancer cells by protecting them from immunoelimination mediated by DR5 activation [43–45]. Here, TNFRSF10B is linked to cancer.